Skip to main content

Sarah M. Kattakuzhy, MD

Academic Title:

Assistant Professor

Primary Appointment:

Medicine

Additional Title:

Clinical and Administrative Director, DC Partnership for HIV/AIDS Progress

Location:

810 7th Street, NE Room 2-140 Washington, DC 20002

Phone (Primary):

443-691-4638

Fax:

301-451-5799

Education and Training

2004                           BS, Biology, BS, Psychology, Virginia Commonwealth University

2009                           MD, Eastern Virginia Medical School

2009-2010                  Internship, Internal Medicine, George Washington University

2010-2012                  Residency, Internal Medicine, George Washington University 

Biosketch

I am an academic clinician investigator, with a focus in viral hepatitis and HIV. During medical training and subsequent chief residency, I developed expertise in teaching and innovative program development, serving both my residency program and the surrounding community. As a clinician within the National Institute of Allergy and Infectious Disease, Laboratory of Immunoregulation clinic, I was immersed in clinical trials methodology, regulation, and oversight. I served as the evaluating provider for several research protocols, gaining experience in advanced HIV treatment and the novel use of directly-acting antiviral (DAA) therapy for hepatitis C.

In 2014 I transitioned to the Institute of Human Virology, where I now serve as Assistant Professor in the University of Maryland School of Medicine, and simultaneously lead the DC Partnership for HIV/AIDS Progress Viral Hepatitis Program as Clinical and Administrative Director. In this capacity, I have staffed multiple viral hepatitis clinics at the NIH and in District of Columbia community healthcare centers, to provide both research-related and standard clinical care in an urban cohort representative of the HCV epidemic. I served as the lead investigator of the SYNERGY study, investigating the limits of short duration combination DAA therapy and predictors of successful treatment, and the ASCEND study, a community-based HCV treatment investigation.

My current research focus is community and implementation-based improvements in the HIV and HCV care continuums, with an emphasis on marginalized populations.

Research/Clinical Keywords

Hepatitis C, HIV, Implementation Science

Highlighted Publications

Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015 Apr;9(2):161-73. doi: 10.1007/s12072-014-9606-9. Epub 2015 Jan 28. Review. PubMed PMID: 25788194.

Kohli A*, Kattakuzhy S*, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24. PubMed PMID: 26595450. *equal contribution

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis. 2016 Feb 15;62(4):440-447. PubMed PMID: 26503379; PubMed Central PMCID: PMC4725378

Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int. 2016 Nov;10(6):861-870. Epub 2016 Jun 21. Review. PubMed PMID: 27328848.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers.. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8. PubMed PMID: 28785771.

Additional Publication Citations

Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis. 2016 Feb 1;62(3):280-288. PubMed PMID: 26521268; PubMed Central PMCID: PMC4706633.

Faldetta KF, Kattakuzhy S, Wang HW, Sereti I, Sheikh V. Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as acute appendicitis in an HIV-infected patient. BMC Infect Dis. 2014 Jun 9;14:313. PubMed PMID: 24910267; PubMed Central PMCID: PMC4057562.

Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014 Sep;43(3):685-96. PubMed PMID: 25169561; PubMed Central PMCID: PMC4159723.

    Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev. 2017 Jan;30(1):23-42. PubMed PMID: 27795306; PubMed Central PMCID: PMC5217793.

      Tang LS, Masur J, Sims Z, Nelson A, Osinusi A, Kohli A, Kattakuzhy S, Polis M, Kottilil S. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World J Hepatol. 2016 Nov 8;8(31):1318-1326. PubMed PMID: 27872683; PubMed Central PMCID: PMC5099584.

      Gross C, Akoth E, Price A, Kattakuzhy S, Silk R, Rosenthal E. HIV/HCV Co-infection: Overcoming Barriers to Treatment. J Assoc Nurses AIDS Care. 2016 Jul-Aug;27(4):524-9. PubMed PMID: 26996983.

      Akoth E, Gross C, Silk R, Rosenthal E, Kattakuzhy SA Practical Approach and Model of Care for HCV Treatment With Direct Acting Antivirals in an Urban Setting. J Assoc Nurses AIDS Care. 2017 Sep - Oct;28(5):680-684. doi: 10.1016/j.jana.2017.04.007. Epub 2017 Apr 26. PubMed PMID: 28506435.

      Research Interests

      In the last three years, my work has centered on the use of directly-acting antivirals in the treatment of hepatitis C mono-infection and co-infection with HIV. This work identified that combination short-duration antiviral therapy appears to be highly successful in early stage liver fibrosis, with moderate response rates in advanced fibrosis. These investigations also revealed that ultra-short DAA-based treatment had poor rates of response, and that patients treated with short-duration DAAs can successfully be re-treated. Overall this work has furthered the understanding of the limits of short duration hepatitis C therapy, with critical implications on a scientific and public health level. As the field of viral hepatitis has evolved, my contributions to the literature have targeted implementation-based improvements in the HCV care cascade, and hard-to-treat subpopulations of the hepatitis C epidemic.

        Clinical Specialty Details

        Internal Medicine

        Awards and Affiliations

        2008                           Primary Care Award and Scholarship, Eastern Virginia Medical School    

        2010                           Intern of the Year, George Washington University Department of Medicine

        2012                           Resident of the Year, George Washington University Department of Medicine and INOVA Fairfax Hospital

        2015                           American Association for the Study of Liver Diseases Young Investigator’s Scholarship

        2015                           European Association for the Study of Liver Diseases Young Investigator’s Scholarship

        2017                           National Institute of Allergy and Infectious Disease Clinical Research Loan Repayment Program Award                  

        Grants and Contracts

        2015-2018                Principal Investigator, Investigator Initiated Grant

                                        ASCEND

                                        Gilead Sciences

                                        Budget: $1,038,000

         

        2016-2017                Principal Investigator, Investigator Initiated Grant

                                        GRAVITY FOCUS Award

                                        Gilead Sciences

                                        Budget: $199,000

         

        2016-2017                Associate Investigator, Investigator Initiated Grant

                                        IHV-Rwanda Community Education Collaboration (IRCEC)

                                        Gilead Sciences

                                        Budget: $165,000

         

        2016-2018                Principal Investigator, Investigator Initiated Grant

                                        GRAVITY

                                        Gilead Sciences

                                        Budget: $593,658

         

        2016-2018                Lead Associate Investigator, Investigator Initiated Grant

                                        ANCHOR

                                        Gilead Sciences

                                        Budget: $265,106.10

         

        2016-2018                Lead Associate Investigator, Investigator Initiated Grant

                                        ANCHOR

                                        Merck & Co.

                                        Budget: $126,000

         

        2017-2022                Clinical and Administrative Director, DC Partnership for HIV/AIDS Progress

                                        Hepatitis Clinical Research Program 5-year Programmatic Grant

                                        Office of AIDS Research

                                        Budget: $9,187,145

        In the News

         

        Professional Activity

        2014 Member, American Association for the Study of Liver Diseases  
        2015 Member, European Association for the Study of Liver Diseases  
        2016 Member, American Public Health Association